Agios Pharmaceuticals | AGIO - Los Gastos De Explotación





Los Gastos De Explotación Cambio Fecha
AbbVie USD 10.81B 13.45B 2025-12
Agios Pharmaceuticals USD 141.54M 11.8M 2025-12
Alnylam Pharmaceuticals USD 965.32M 84.27M 2025-12
Amgen USD 5.9B 773M 2025-12
Arrowhead Research USD 223.22M 10.86M 2025-12
Astellas Pharma JPY 436.66B 16.75B 2025-12
AstraZeneca USD 12.53B 4.16B 2025-12
Bayer EUR 10.33B 126M 2025-12
Biogen USD 1.88B 81.4M 2025-09
BioMarin Pharmaceutical USD 676.18M 131.65M 2025-12
Bristol-Myers Squibb USD 8.3B 10.25B 2025-12
Daiichi Sankyo JPY 468.57B 15.34B 2025-12
Eli Lilly USD 10.31B 1.09B 2025-12
Exelixis USD 362.75M 21.35M 2025-12
Gilead Sciences USD 4.96B 707M 2025-12
GlaxoSmithKline GBP 7.18B 1.42B 2025-12
Incyte USD 1.12B 3.53B 2025-12
Ionis Pharmaceuticals USD 418M 101.1M 2025-12
Merck USD 10.16B 558M 2025-12
Moderna USD 1.54B 259M 2025-12
Nektar Therapeutics USD 85.09M 109.3M 2025-09
Novartis USD 9.86B 115M 2025-09
Novartis USD 9.77B 401M 2025-09
Pfizer USD 12.91B 79.89B 2025-12
Puma Biotechnology USD 49.26M 3.2M 2024-06
Regeneron Pharmaceuticals USD 2.99B 27.97B 2025-12
Roche Holding CHF 21.01B 10.84B 2025-12
Sarepta Therapeutics USD 853.02M 390.78M 2025-12
Vertex Pharmaceuticals USD 1.93B 89.1M 2025-12